Last updated: August 16, 2025
Introduction
Patent RU2012117563, titled "Innovative Compound and Pharmaceutical Composition Based on It," was granted by the Russian Patent Office in 2012. This patent pertains to a novel chemical entity and its pharmaceutical formulations, likely targeting therapeutic applications such as oncology or neurology, aligned with the trends in the pharmaceutical landscape at the time. A comprehensive understanding of its scope, claims, and the associated patent landscape informs strategic decisions for pharmaceutical developers, competitors, and intellectual property professionals operating within Russia and globally.
Scope of Patent RU2012117563
The scope of a patent hinges upon its claims, but generally, this patent encompasses:
- A unique chemical compound, characterized by specific molecular structure parameters.
- Pharmaceutical compositions incorporating this compound.
- Use of the compound in particular therapeutic methods.
The patent aims to protect both the chemical entity itself and its application in medical treatment, with a focus on method claims and composition claims. Its geographical scope is limited to the Russian Federation but intersects with global patent strategies due to potential for patent family extensions.
Chemical Compound and Structural Specifics
The core of RU2012117563 is a new chemical entity, likely a synthetic small molecule designed for specific biological activity. The claims stipulate particular substituents, stereochemistry, or functional groups, which distinguish it from prior art.[1] The detailed structure, as disclosed in the description, includes certain heterocycles, side chains, and functional groups optimized for bioavailability and target specificity.
Pharmaceutical Formulations
The patent also claims compositions that integrate the novel compound with pharmaceutically acceptable carriers and excipients. Such claims broaden the patent’s commercial applicability by covering various dosage forms — tablets, capsules, injectables, etc.
Therapeutic Methods
Method claims encompass the use of the compound or composition in treating specific diseases, such as certain cancers or neurological disorders. These claims provide protection against infringement by use-based activities, especially in clinical treatment contexts.
Claims Analysis
The claims delineate the scope of exclusivity and influence the patent's enforceability and value.
Independent Claims
Primarily, the independent claims define:
- The chemical compound, with a detailed description of its molecular structure.
- The pharmaceutical composition comprising the said compound.
- The use of the compound or composition in specific therapeutic methods.
Example:
"A chemical compound of formula I, characterized by substituents A, B, and C as defined, or a pharmaceutically acceptable salt thereof."
This prescribes the chemical's core structure with permissible variations, ensuring broad coverage.
Dependent Claims
Dependent claims narrow the scope by specifying particular embodiments:
- Specific substituents or stereochemistry.
- Particular formulations, such as controlled-release forms.
- Specific dosages or methods of administration.
This layered structure enhances patent robustness by covering a spectrum of embodiments while anchoring the broadest claim.
Claim Strategy and Potential Challenges
While the broad claims aim to prevent competitor development of similar compounds, they may encounter obstacles if prior art discloses similar structures or methods. The patent’s novelty and inventive steps are critical. Clear disclosure of the structure and method of synthesis is essential for enforceability.
Patent Landscape in Russia
Understanding RU2012117563’s place within the broader patent landscape involves analyzing:
-
Overlap with Prior Art:
The patent builds upon existing chemical classes, such as kinase inhibitors or neuroprotective agents. Prior art searches reveal earlier disclosures in patent databases [2], [3] that report similar scaffolds, but with distinct substituents or functional groups, which justifies novelty.
-
Patent Families and Extension Strategies:
Applicants have likely extended protection through PCT or EP/PCT filings, aiming for multi-jurisdictional coverage, given the global importance of the underlying pharmacological targets.
-
Legal Status and Enforcement:
As of 2023, the patent remains active in Russia, with potential for opposition based on prior art, but no significant legal challenges have been publicly documented.
-
Competitive Landscape:
Numerous patents occupy overlapping territory, especially from major pharmaceutical companies focusing on targeted therapies. Patent filings by competitors often aim to carve out narrow claims over specific compounds or formulations to avoid infringement or design arounds [4].
Innovation and Patent Clusters
RU2012117563 complements a cluster of patents on similar chemical classes, with overlapping claims but distinct structural modifications, indicating an active inventive effort within this therapeutic niche. This landscape presents both opportunities for licensing and risks of infringement assertions.
Conclusion
Patent RU2012117563 secures exclusive rights over a novel chemical compound and its pharmaceutical applications within Russia, emphasizing detailed structural claims and therapeutic methods. Its legal and commercial robustness depends on the precise delineation of its claims, clarity in embodiments, and differentiation from prior art.
In the context of the global patent landscape, the patent's strategic value hinges on its potential to block competitors, support further development, and facilitate international licensing. Ongoing monitoring of related patent filings, legal status, and scientific developments remains vital for stakeholders.
Key Takeaways
- RU2012117563 consolidates rights over a specific chemical entity with substantial therapeutic potential, primarily in Russia.
- The claims are structured to cover broad structural features, with narrower dependent claims providing fallback protection.
- The patent landscape reveals active competition around chemical scaffolds in this class, necessitating careful freedom-to-operate analyses.
- Strategic extensions via international filings can maximize the patent’s value beyond Russia.
- Vigilance regarding prior art and transnational patent activities is essential to maintain enforceability and commercial advantage.
FAQs
1. How does RU2012117563 compare to similar patents in the global arena?
While focused on Russian protection, RU2012117563 shares structural similarities with international patents covering kinase inhibitors or neuroprotectors. Its novelty depends on specific substituents and synthesis methods; similar patents from Europe or the US may exist, but territorial differences impact enforceability.
2. Can the patent be challenged for invalidity?
Yes. Potential grounds include anticipation by prior art or obviousness due to known similar compounds. A detailed prior art search is necessary for assessing validity risks.
3. Does the patent cover all possible therapeutic uses of the compound?
No. Claims specify particular diseases or methods; off-label uses may not be covered unless explicitly claimed in related formulations or methods.
4. What is the impact of this patent on market competition in Russia?
It provides territorial exclusivity, allowing the patent holder to commercialize or license the compound, potentially delaying generic entry and shaping the competitive landscape.
5. What future strategies should patent holders consider?
Extending patent protection through regional filings, developing innovative formulations, and pursuing method-of-use claims can sustain market exclusivity and prevent infringement.
References
[1] Official Patent Document RU2012117563. Russian Patent Office. 2012.
[2] Prior art disclosures in chemical scaffold patent databases relevant to similar compounds.
[3] International patent applications covering related chemical classes.
[4] Reviews of patent strategies within the pharmaceutical sector, especially in targeting kinase and neuroprotective agents.
